Summit Therapeutics

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31
Revenue
$0
$0
$-235
Gross Profit
-20
-27
-840
EBITDA
-44,749
-42,362
-33,334
EBIT
-44,769
-42,389
-33,939
Net Income
-60,385
-43,473
-36,567
Net Change In Cash
0
0
-235
Free Cash Flow
-32,912
-30,138
-19,461
Cash
28,754
61,294
71,425
Basic Shares
707,904
701,785
701,660

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$0
$704
$1,809
$860
Gross Profit
-2,050
-1,809
1,809
860
EBITDA
-87,686
-60,803
-83,731
-51,475
EBIT
-89,736
-63,317
-86,186
-53,478
Net Income
-614,928
-74,381
-86,147
-52,697
Net Change In Cash
0
704
1,809
860
Free Cash Flow
-76,888
-42,206
-72,893
-48,532
Cash
71,425
348,607
71,791
66,417
Basic Shares
619,646
193,336
92,239
69,524

Earnings Calls

Quarter EPS
2024-09-30
-$0.08
2024-06-30
-$0.09
2024-03-31
-$0.06
2023-12-31
-$0.05